RedUction of LDL-C with PCSK9 InhibiTion in HEteRozygous Familial HyperchOlesteRolemia Disorder Study-2 - RUTHERFORD-2


Patients with heterozygous familial hypercholesterolemia (HeFH) have markedly elevated low-density lipoprotein cholesterol (LDL-C). Currently available medications, including statins, typically reduce LDL-C by 50-60%. The current trial sought to assess the safety and efficacy of evolocumab, a PCSK9 inhibitor, in further reducing LDL levels in patients with HeFH already on statin therapy.